Modeling shows the NK3R antagonist, ACER-801, reduces treatment-induced vasomotor symptoms. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract does not include a full ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback